The incidence of classical acute (a) GVHD grade 2-4 and 3-4 was 18% and 8% by day 100 and 29% and 13% by day 180 if late onset aGVHD is included. No factors included in a univariate analysis (which included age, diagnosis, disease status, HCT-CI, donor type, CMV risk and cell dose) significantly impacted TRM. Results: TRM was low at 7% at 1 year and 11% at 2 and 3 years respectively. 58% of patients had a HCT-CI score of 0, 32% a score of 1 or 2 with 3 patients having a score of 3 or higher. Matched sibling donors were used in 13 instances with the remaining being fully matched unrelated donors.
27 (87%) were in first complete remission (CR1). 24 patients (77%) had high risk disease by standard diagnostic criteria. 30 had B-ALL and 10 were Philadelphia chromosome positive. Thirty-one patients with a median age of 43 (23-67) met the criteria for this case review. Short course MTX and ciclosporin were used for GVHD prophylaxis. All patients were conditioned with fludarabine 25mg/m 2/day for 5 days and cyclophosphamide 1g/m 2/day for 2 days. These were consecutive patients until 2015 then only those considered unfit for FMC conditioning as per the UKALL 2014 protocol. Methods: First transplant patients between October 2006 and June 2018 were reviewed. We report the outcomes of 31 patients with ALL transplanted using a NMA conditioning without T cell depletion. Use of truly non-myeloablative (NMA) conditioning reduces toxicity in other contexts but outcome data for ALL patients after NMA transplants is lacking. Kian Ben-Jacob (Jacob Hochhalter) - Creation of a Digital Twin for a High-Power Model Rocket as Proof of ConceptĪiden Beukema (Randall Irmis) - Inferring CO2 Levels of Late Triassic Paleoclimate From Carbonate Nodules Found in South-Eastern Utah Mudstone.P001 Low treatment related mortality and relapse leading to excellent outcomes after allogeneic transplantation for acute lymphoblastic leukaemia using a non-myeloablative conditioning without T CELL depletion Mary Lynn Savoie 1,2, Jeff K Davies 3,4, Jamie Cavenagh 3,4, Heather Oakervee 4, Jonathan Sive 4, Matthew Smith 4, Deborah Anderson 4, John Gribben 3,4, Bela Wrench 3,4 1 University of Calgary, Calgary, Canada, 2 Tom Baker Cancer Centre, Calgary, Canada, 3 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, 4 St Bartholomew's Hospital, Barts Health NHS Trust, Barts Cancer Centre, London, United Kingdomīackground: Allogeneic hematopoietic stem cell transplantation is routinely offered to patients with high-risk or advanced ALL in the hopes of improving outcomes.
Maxwell Austin (Andrew Roberts) - Organocatalyzed Macrocyclization of Small and Large Peptidesĭua Azhar (Sophie Caron) - Quantifying the Relationship Between Relative Brain Size and Sensory Neuron Population Across the Drosophila Phylogenyĭrew Becker (Jennifer Weidhaas) - Analysis of Fecal Coliform Indicators in Upper Emigration Creek pseudoobscura pseudoobscura (USA) subspecies. Pooja Annigeri (Nitin Phadnis) - The identification and characterization of a second autosomal gene that works in association with Overdrive to create hybrid incompatibility within Drosophila pseudoobscura in Bogota and D. Nicolai Andreas (Tao Gao) - Analysis of Zn Deposition and Dendrite Formation in Redox Flow Batteries Naren Anandh (Shundana Yusaf) - Towards Re-Inventing Traditional Materialsĭerek Anderson (Sujee Jeyapalina) - Quantifying the antibacterial properties of silver and strontium-doped fluorapatite Emily Adler (Stella Mosher) - Charcoal Morphotypes and Geochemical Responses to Paleofire in the South African FynbosĪwais Ahmad (Owen Chan) - The Effect of Norepinephrine on Glutamate Release in the VMH during Hypoglycemia
0 kommentar(er)
